Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Icad Inc Market Cap
The Icad Inc (ICAD) share price is expected to increase by 131.48% over the next year. This is based on calculating the average 12-month share price estimate provided by 4 stock analysts who have covered ICAD. Price targets range from $2.5 at the low end to $9 at the high end. The current analyst consensus for ICAD is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Icad Inc has a total of 4 Wall St Analyst ratings. There are 4 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Icad Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of ICAD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Frank Takkinen Lake Street | Buy | $5 | Maintains | Jul 19, 2023 |
| David Turkaly JMP Securities | Outperform | $4 | Maintains | Apr 13, 2023 |
| Francois Brisebois Oppenheimer | Outperform | $4 | Maintains | Apr 4, 2023 |
| Frank Takkinen Lake Street | Buy | $2.5 | Maintains | Mar 29, 2023 |
| Marie Thibault BTIG | Buy | $3 | Maintains | Mar 29, 2023 |
| David Turkaly JMP Securities | Market Outperform | $7 | Maintains | Sep 1, 2022 |
| Frank Takkinen Lake Street | Buy | $8 | Maintains | Aug 11, 2022 |
| Marie Thibault BTIG | Buy | $8 | Maintains | Jun 24, 2022 |
Guggenheim | Neutral | Downgrade | Jan 18, 2022 | |
| Francois Brisebois Oppenheimer | Outperform | $16 | Maintains | Jan 5, 2022 |
| David Turkaly JMP Securities | Market Outperform | $18 | Maintains | Nov 10, 2021 |
Guggenheim | Buy | Initiates | Apr 22, 2021 | |
BTIG | Buy | Initiates | Mar 23, 2021 | |
Oppenheimer | Outperform | Initiates | Feb 26, 2021 | |
Cantor Fitzgerald | Overweight | Initiates | Jan 29, 2021 | |
B. Riley Securities | Buy | Initiates | Dec 3, 2020 | |
B. Riley FBR | Buy | Initiates | Dec 3, 2020 | |
JMP Securities | Market Outperform | Initiates | Feb 5, 2020 | |
Dougherty & Co. | Buy | Initiates | Dec 20, 2019 | |
Craig-Hallum | Buy | Initiates | Feb 13, 2013 |
When did it IPO
1992
Staff Count
67
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Ms. Dana R. Brown
Market Cap
$49.8M
In 2023, ICAD generated $17.3M in revenue, which was a decrease of -12.54% from the previous year. This can be seen as a signal that ICAD's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 04 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - ProFound Health and Cascaid Health are launching a partnership to provide AI-powered mammography, aimed at increasing access for all patients, set to launch in Q1 2025.
Why It Matters - ProFound Health's AI-powered mammography initiative could disrupt the healthcare sector, potentially increasing market share and driving growth in telemedicine, impacting investor sentiment and stock valuations.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - ProFound Health and Cascaid Health are launching a virtual care partnership in Q1 2025 to provide AI-powered mammography access to all patients.
Why It Matters - ProFound Health's AI-powered mammography initiative may enhance healthcare accessibility, potentially driving growth in the telehealth sector and attracting investor interest in digital health innovations.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - iCAD, Inc. (NASDAQ: ICAD) will hold its Q3 2024 earnings conference call on November 13, 2024, at 4:30 PM ET, featuring key executives and analysts.
Why It Matters - The upcoming Q3 earnings call for iCAD, Inc. provides insights into the company's financial performance and strategic direction, influencing stock valuation and investor sentiment.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - iCAD, Inc. reported its financial and operational results for Q3 and the first nine months of 2024, focusing on its AI-powered breast health solutions.
Why It Matters - iCAD's financial results reflect its growth and innovation in AI-powered breast health solutions, impacting investor sentiment and potential stock performance.
Wed, 06 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - iCAD, Inc. (NASDAQ: ICAD) will participate in the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, in NYC, with management available for one-on-one meetings.
Why It Matters - iCAD's participation in a key conference highlights its commitment to growth and innovation in AI-powered healthcare, potentially attracting investor interest and impacting stock performance.
Wed, 16 Oct 2024
Sentiment - NEUTRAL
Source - Newsfile Corp
Summary - iCAD, Inc. will present at the LD Micro Main Event XVII on October 29-30, 2024, with CEO Dana Brown speaking at 10:30 a.m. The company focuses on AI-powered breast health solutions.
Why It Matters - iCAD's participation in a major investor conference highlights its growth potential and focus on innovative cancer detection solutions, which could attract investor interest and impact stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
